David Mott

David Mott is a prominent private investor and board member, currently operating through Mott Family Capital. He has an extensive background in the healthcare sector, particularly in biotechnology and venture capital.

Professional Background

• Current Roles:

  • Private Investor at Mott Family Capital since February 2020.
  • Chairman of several companies, including:
    • Ardelyx, Inc. (since 2008)
    • Mersana Therapeutics, Inc. (since 2013)
    • Epizyme, Inc. (since 2009)
    • Adaptimmune (since 2014) .123

• Previous Experience:

  • Served as a General Partner at New Enterprise Associates (NEA) from September 2008 to February 2020, where he led the healthcare investing practice.
  • Held significant roles at MedImmune LLC, where he was President and CEO from October 2000 to July 2008 and held various executive positions from April 1992 to September 2000 .134

Education

David Mott holds a Bachelor of Arts degree in Economics and Government from Dartmouth College .12

Contributions and Impact

Mott has been instrumental in guiding several biotech companies through his leadership roles on their boards. His experience spans multiple successful exits in the biotech sector, earning him recognition in investment circles .45 His strategic insights and investment acumen have made him a key figure in the healthcare investment landscape.